Navigation Links
Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions

EMERYVILLE, Calif., Aug. 25 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its management team, naming Michael D. Coffee, Senior Vice President, Sales and Marketing, and Amy K. Patick, PhD, Vice President, Research.

Mr. Coffee will report to Gregory Went, PhD, Chief Executive Officer and Chairman of Adamas and will be responsible for US sales and marketing, identification of ex-US partners and new product initiatives. His initial focus will be on developing international partnerships for Adamas' infectious disease and CNS programs, and developing the specialty pharmaceutical business unit.

Dr. Patick will report to Efraim Shek, PhD, Senior Vice President, Research and Development, and will be responsible for Adamas' Research activities aimed at establishing proof-of-concept of Adamas' infectious disease and neurology drug development programs. In this role, Dr. Patick will also lead the company's efforts to build its scientific presence and collaborations with anti-infective and CNS community leaders.

"These appointments reflect Adamas' accelerated trajectory and commitment to engage experienced leaders to help advance our CNS programs and our lead program, Triple Combination Antiviral Drug (TCAD) therapy for seasonal and novel H1N1 influenza," said Gregory Went, PhD, Chief Executive Officer and Chairman of Adamas. "Mr. Coffee and Dr. Patick are veteran pharmaceutical industry executives whose extensive experience will be instrumental in developing and executing our long-term strategy in neurology and infectious disease."

Adamas was founded in 2004 to address vexing global health problems such as Parkinson's disease and dementia, and infectious diseases such as influenza. Adamas invents precisely calibrated fixed-dose therapeutic treatments in controlled release combinations that overcome the limitations of monotherapy and conventional dosage forms. The company has three product candidates in development:

  • ADS-8902, its proprietary triple combination antiviral drug (TCAD) therapy for flu
  • ADS-5101, a proprietary once-daily extended release (ER) formulation of amantadine hydrochloride for the symptomatic treatment of Parkinson's disease and other disorders, and
  • ADS-8703, a proprietary fixed-dose combination for the symptomatic treatment of dementia.

About Mr. Coffee and Dr. Patick

Mr. Coffee brings more than 30 years sales, marketing and senior management experience working with emerging as well as large pharmaceutical companies. Prior to Adamas he served as Chief Business Officer for Avigen, Inc. He co-founded the Alekta Group, LLC to provide a comprehensive range of pharmaceutical development consulting services. Mr. Coffee also held positions as President and Chief Operating Officer of Amarin Corporation plc and Amarin Pharmaceuticals Inc., President and Chief Operating Officer of Elan Pharmaceuticals, North America, and President and Chief Operating Officer of Athena Neurosciences, Inc. Mr. Coffee was Vice President of Marketing & Sales for Miles Pharmaceuticals, the U.S. division of Bayer AG, and Vice President of Sales for USV Laboratories. He began his career with Sandoz Pharmaceuticals. Mr. Coffee received a BS in Biology from Siena College.

Dr. Amy Patick joins Adamas with more than 20 years of pharmaceutical industry experience. Amy started her professional career as Research Investigator with Bristol-Myers Squibb and then joined Agouron Pharmaceuticals (later on Pfizer Global R&D), where she worked from 1994 - 2007 in various leadership positions leading up to her role as Head of Biology, Antiviral Therapeutic Area. In this capacity, Dr. Patick led the preclinical effort in the successful approval of Viracept (nelfinavir) for HIV infection. Most recently, Dr. Patick was Vice President, Biological Sciences at Genelabs Technologies. Dr. Patick earned her PhD in Medical Microbiology from the University of Wisconsin, and had postdoctoral training at the Mayo Clinic/Foundation in Rochester, MN. She is the co-author of more than 70 scientific publications and holds over 20 patents. She is the current President of the International Society for Antiviral Research.

About TCAD Therapy

Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, act synergistically to provide a much higher level of antiviral activity than single or double drug combination therapies. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy for influenza A in North America during this upcoming flu season.

About Adamas

Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify and match proven drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India. For more information about Adamas, please visit

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adamas Pharmaceuticals Raises $40 Million in Series D Financing
2. Raptor Pharmaceuticals Raises $5 Million
3. Cumberland Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 27, 2009
4. The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc.
5. NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting
6. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
7. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
8. Sound Pharmaceuticals Receives an Office of Naval Research Award for Its Hearing Loss Research and Development
9. Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
11. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association of ... local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, the ... that inspires people to collaborate in improving their local communities and help give ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
(Date:11/24/2015)... ... , ... Dr. Rodney E. Willey , has answered a new calling – to relieve ... provides treatment for snoring and sleep apnea through oral appliance therapy. He ... Disorders in the US, one of four in the Illinois area. , Dr. Willey’s ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading ... driven by social media and the generosity of people around the world. On December ... media networks to give – and share the personal stories behind those gifts. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Robert Yeager ... Report . Throughout the past year there have been multiple breakthroughs and challenges as ... this transition, PharmMD has enabled their customers and partners to stay ahead of the ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  In the pharmaceutical industry, companies want to ... quickly uncover new insights, tactics and strategies that will ... --> However, organizations often find it is ... ensure that all rules and regulations are met to ... barrier to efficiently launching market research projects is the ...
(Date:11/24/2015)... , 24. November 2015 Avery ... Pacemaker Systems, ist erfreut, die Berufung von ... bekannt geben zu können. ... --> Foto - ... (Schweden). Von 1984-1986 war er Fellow des ...
(Date:11/24/2015)... Sectra (STO: SECT B) announces ... a multi-year agreement to deploy Breast Imaging PACS ... provide the Breast Center a future-proof platform capable of expanding ... B) announces that Breast Center of Acadiana has ... Imaging PACS in its two freestanding imaging centers. This investment ...
Breaking Medicine Technology: